TAMPA, Florida -- Buccaneers cornerback Aqib Talib has been suspendedfour games by the NFL for the use of performance enhancing drugs.

In a statement released by the team, Talib said, "Around the beginning of training camp, I made a mistake by taking an Adderall pill without a prescription.This is especially regrettable because for the past several months with Coach Schiano's help, I've worked very hard to improve myself, professionally and personally, as a player and a man.

"I am truly sorry to my teammates, coaches and Buccaneers fans, and I'm disappointed in myself. I will work diligently every day of this suspension to stay in top football shape and be ready to help this team in the second half of the season.I have chosen to be immediately accountable for the situation I put myself in, which is why I will not exercise my appeal rights and will begin serving the suspension immediately."

Adderall is a stimulant on the NFL's banned substance list. Talib will miss the nextfour games, costing him over $400,000. He'll make his return to the Bucs roster on November 5.

Buccaneers head coach Greg Schiano has worked extensively with the cornerbacks during practice sessions, and in particular Talib. He said, "We are disappointed to learn that Aqib Talib will be suspended for four games, which will begin with our game tomorrow against Kansas City. I have spoken with Aqib, and he knows that he made a poor decision that let our team down. Certainly, other players will have the opportunity to step up while he serves this suspension."

The Buccaneers promoted defensive end Markus White from the practice squad to replace Talib's spot on the 53-man roster. The Buccaneers cornerback position is already an ailing one. Eric Wright is coming off a concussion and missed some practices this week. Anthony Gaitor was just placed on the Injured Reserved, and EJ Biggers is still trying accumulate his strength since coming off the IR. Rookie Leonard Johnson and Myron Lewis will both likely see more playing time in Talib's absence.

Read or Share this story: